Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update
Rhea-AI Summary
Coherus Oncology (NASDAQ: CHRS) reported full-year and Q4 2025 results, highlighting commercial growth for LOQTORZI, major debt reduction, cash position and pipeline progress. LOQTORZI revenue more than doubled to $40.8M in 2025. Secured and convertible debt was reduced ~90% to $38.8M. Cash and marketable securities totaled $172.1M at year-end. The company reported a 2025 net loss of $183.1M and ongoing R&D investment in tagmokitug and casdozokitug with multiple clinical readouts expected in 2026.
Notable clinical data include a 6-year OS median of 64.8 months vs 33.7 months for chemotherapy in JUPITER-02 (HR 0.62), and a prior Phase 2 casdozokitug CR rate of 17%.
Positive
- LOQTORZI revenue more than doubled to $40.8M in 2025
- Secured and convertible debt reduced ~90% to $38.8M
- Cash and marketable securities of $172.1M at December 31, 2025
- JUPITER-02 6-year OS median 64.8 months vs 33.7 months (HR 0.62)
Negative
- Net loss of $183.1M in 2025, reflecting continued operating deficits
- Significant R&D spend of $108.9M in 2025
- Equity offerings raised proceeds (~$47.0M in Feb 2026) causing shareholder dilution
News Market Reaction – CHRS
On the day this news was published, CHRS gained 1.04%, reflecting a mild positive market reaction. Argus tracked a peak move of +8.1% during that session. Argus tracked a trough of -5.5% from its starting point during tracking. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $3M to the company's valuation, bringing the market cap to $308M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
CHRS is up 3.41% while peers show mixed moves: AGEN +1.37%, TIL +3.74%, but GLSI -3.43% and MCRB -2.04%. No broad biotech earnings-driven trend is evident.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 06 | Q3 2025 earnings | Positive | -10.1% | LOQTORZI growth, higher cash, but continued losses from continuing operations. |
| Aug 07 | Q2 2025 earnings | Positive | -7.1% | LOQTORZI growth and large UDENYCA divestiture gain boosting cash. |
| May 12 | Q1 2025 earnings | Positive | -19.1% | LOQTORZI launch progress and UDENYCA sale alongside ongoing net losses. |
| Mar 10 | FY 2024 earnings | Positive | +1.0% | 2024 revenue growth and planned UDENYCA divestiture to fund oncology focus. |
| Nov 06 | Q3 2024 earnings | Positive | +13.3% | Strong UDENYCA and LOQTORZI revenue growth with moderate net loss. |
Earnings releases have typically been followed by negative moves (average -4.41%), despite generally growth-focused updates.
Over the past five earnings cycles since Nov 2024, Coherus has consistently highlighted LOQTORZI revenue growth, rising cash balances, and a shift from biosimilars toward oncology. Updates in 2025 emphasized LOQTORZI ramp, the UDENYCA divestiture for up to $558.4M, and advancing casdozokitug and CCR8 programs. Despite these developments, the stock often moved lower after earnings, suggesting a history of cautious market reactions to financial and pipeline progress.
Historical Comparison
In the past year, CHRS posted 5 earnings updates with an average move of -4.41%. Today’s +3.41% reaction to full-year 2025 results runs counter to that trend.
Across these earnings, Coherus has progressed from a biosimilars-heavy model toward an oncology-focused portfolio, with LOQTORZI revenue ramping each quarter and divestiture proceeds and financings used to support casdozokitug and CCR8 programs.
Regulatory & Risk Context
Coherus has an S-3 shelf filed on 2025-11-13 to offer up to $150.0 million of mixed securities. It has been used via multiple 424B5 prospectus supplements in 2026, including an ATM program and common stock offerings, providing flexibility to raise additional capital.
Market Pulse Summary
This announcement details strong LOQTORZI growth to $40.8 million in 2025, substantial debt reduction to $38.8 million, and year-end liquidity of $172.1 million, alongside ongoing net losses. Clinical updates highlight encouraging survival and response data for LOQTORZI and casdozokitug. Recent equity financings and the $150.0 million shelf provide capital flexibility but also add dilution risk. Key metrics to watch include LOQTORZI uptake, cash usage, and 2026 clinical readouts.
Key Terms
pd-1 inhibitor medical
il-27 medical
ccr8 medical
t regulatory cells medical
overall survival (os) medical
hazard ratio (hr) medical
phase 1b medical
phase 3 medical
AI-generated analysis. Not financial advice.
– LOQTORZI® net revenue more than doubled to
– Reduced secured and convertible debt by
–
– Conference call today at 4:30 p.m. Eastern Standard Time –
REDWOOD CITY, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today reported financial results for the full year and fourth quarter 2025, and provided an overview of recent business highlights.
“We are pleased with our progress in 2025, having doubled LOQTORZI sales while completing the transformation from a biosimilars company to an innovative oncology company focused on overcoming immune resistance in cancer. At the same time, we continued to reduce our overall debt since its peak in 2024 by over
“We are aggressively advancing casdozokitug, our first-in-class IL-27 targeting antibody in 1L hepatocellular carcinoma, which demonstrated a
“Tumor targeted T regulatory cell depleting agents have broad potential applicability in combination with immune agents like TCE and toripalimab, ADCs, T-cell engagers and radiotherapy,” said Theresa LaVallee, PhD, Coherus Chief Scientific and Development Officer. “With a potentially best-in-class molecule we look forward to advancing tagmokitug combinations both with partners and with LOQTORZI.”
RECENT BUSINESS HIGHLIGHTS
LOQTORZI® (toripalimab-tpzi) Commercial Updates
- LOQTORZI net revenue for Q4 2025 was
$12.4 million , an11% increase over$11.2 million in Q3 2025 and a64% increase over$7.5 million in Q4 2024. Growth in Q4 2025 was driven largely by higher patient demand from both new account starts as well as repeat use in existing accounts. Average duration of treatment among existing patients also continued to grow. - LOQTORZI remains the only FDA-approved and available treatment in the U.S. for recurrent, locally advanced or metastatic nasopharyngeal carcinoma (NPC,) representing an overall
$250 million addressable market. - In December 2025, compelling six-year overall survival (OS) follow-up results from the Phase 3 JUPITER-02 trial evaluating LOQTORZI® plus chemotherapy in recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) were presented at ESMO Asia. In this exploratory post-hoc analysis, patients receiving LOQTORZI plus gemcitabine and cisplatin achieved a median OS of 64.8 months, nearly double that of chemotherapy alone (33.7 months), and an observed
38% reduction in risk of death (HR 0.62;95% CI, 0.45–0.85).
ADVANCEMENT OF INNOVATIVE, NEXT-GENERATION ONCOLOGY PIPELINE
Tagmokitug is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding.
- Preclinical and clinical biomarker research for tagmokitug was published in the December 2025 issue of Molecular Cancer Therapeutics, describing the high selectivity, picomolar binding affinity and significant effector mediated killing of CCR8+ cells. The findings showed that tagmokitug demonstrated no off-target binding and selectively eliminated CCR8+ T regulatory cells and not other T cells, supporting its potential as an anti-cancer treatment.
- The Phase 1b tagmokitug/toripalimab combination dose optimization studies in 2L HNSCC and 2L upper GI adenocarcinoma cancers are underway, with initial data readouts expected in mid-2026.
- A Phase 1b study evaluating the tagmokitug/toripalimab combination, with and without chemotherapy, in 1L and 2L esophageal squamous cell carcinoma (ESCC), respectively, is underway with a first data readout expected in 2H 2026.
- A Phase 1b/2a study evaluating tagmokitug/toripalimab combination in 4L+ colorectal cancer is enrolling patients and initial data is expected in 2H 2026.
- A Phase 1b clinical study in patients with metastatic castration-resistant prostate cancer (mCRPC) in combination with pasritamig, a T-cell engaging bispecific antibody, is anticipated to begin in 2H 2026.
Casdozokitug is a first-in-class IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first line uHCC (unresectable hepatocellular carcinoma) to assess treatment benefit, safety and response biomarkers.
- Enrollment is ongoing in the randomized Phase 2 trial of casdozokitug/toripalimab/bevacizumab in 1L uHCC, with the first data readout expected in mid-2026.
- Data presented during ASCO GI 2025 demonstrated a
38% overall response rate and a17% complete response rate with the addition of casdozokitug to the current standard of care.
EQUITY FINANCINGS
- In October 2025, the Company sold 4,634,995 shares of common stock and warrants with an exercise price of
$0.01 per share to purchase 463,498 shares of common stock for net proceeds of approximately$7.9 million . In February 2026, Coherus sold 28,600,000 shares of its common stock in public offering for proceeds of approximately$47.0 million , net of Underwriters’ discounts and commissions.
FOURTH QUARTER 2025 FINANCIAL RESULTS
Net revenue from continuing operations was
Cost of goods sold (COGS) from continuing operations was
Research and development (R&D) expenses from continuing operations were
Selling, general and administrative (SG&A) expenses from continuing operations were
Interest expense from continuing operations was
Net (loss) from continuing operations for the fourth quarter of 2025 was
Non-GAAP net loss from continuing operations for the fourth quarter of 2025 was
Cash, cash equivalents and marketable securities totaled
Conference Call Information
When: Monday, March 9, 2026, starting at 4:30 p.m. Eastern Standard Time
To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register-conf.media-server.com/register/BI343f960d41224739b123cc4c86fdce7a
Webcast: https://edge.media-server.com/mmc/p/2otjwz7w
A live and archived webcast will be available on the “Investors” section of the Coherus website at https://investors.coherus.com/events-presentations.
Please dial in 15 minutes early to ensure a timely connection to the call.
About Coherus Oncology
Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, head & neck, colorectal and other cancers. The Company’s strategy is to grow sales of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as through its partners, driving sales multiples and synergies from proprietary combinations.
Coherus’ innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. Tagmokitug is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies in patients with advanced solid tumors, including head and neck squamous cell carcinoma, colorectal cancer, gastric cancer, and esophageal cancer. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line hepatocellular carcinoma.
For more information about LOQTORZI, including the U.S. Prescribing Information and important safety information, please visit www.loqtorzi.com.
Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements contained in this press release may be identified by the use of words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. These statements are based on the Company's current beliefs and expectations. Such forward looking statements include, but are not limited to, statements regarding Coherus’ expectations about identifying sales multiples and synergies; the ability of Coherus’ I-O pipeline to enhance outcomes for cancer patients; projections for cash runway; the ability to reduce risk for Coherus’ pipeline; expectations for the timing when Coherus will be able to commence future clinical studies or receive clinical data for its product candidates; Coherus’ ability to enter into additional partnerships; Coherus’ ability to grow revenues; and Coherus’ expectations about total addressable opportunity for each of its product candidates.
Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus’ actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties inherent in the clinical drug development process; risks related to Coherus’ dependence on an ability to raise funds in the future, which may not be available on acceptable terms or at all; risks related to Coherus’ existing and potential collaboration partners; risks of Coherus’ competitive position; the risks and uncertainties of the regulatory approval process, including the speed of regulatory review and the timing of Coherus’ regulatory filings; the risk of FDA review issues; and the risks and uncertainties of possible litigation. All forward-looking statements contained in this press release speak only as of the date of this press release. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the significant risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus’ business in general, see Coherus’ Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission on or about the date of this press release, including the section therein captioned “Risk Factors” and in other documents Coherus files with the Securities and Exchange Commission. Coherus’ results for the quarter and full year ended December 31, 2025 are not necessarily indicative of its operating results for any future periods.
LOQTORZI®, whether or not appearing in large print or with the trademark symbol, is a registered trademark of Coherus Oncology, Inc.
©2026 Coherus Oncology, Inc. All rights reserved.
Coherus Contact Information:
For Investors & Media:
Carrie Graham
Vice President, Investor Relations and Advocacy
IR@coherus.com
| Coherus Oncology, Inc. Condensed Consolidated Statements of Operations (in thousands, except share and per share data) | ||||||||||||||||
| Three Months Ended | Year Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2025 (unaudited) | 2024 (unaudited) | 2025 (unaudited) | 2024 (audited) | |||||||||||||
| Net revenue | $ | 12,748 | $ | 7,733 | $ | 42,172 | $ | 26,389 | ||||||||
| Costs and expenses: | ||||||||||||||||
| Cost of goods sold | 4,045 | 2,750 | 13,814 | 8,727 | ||||||||||||
| Research and development | 30,974 | 20,759 | 108,888 | 91,833 | ||||||||||||
| Selling, general and administrative | 23,609 | 29,608 | 100,604 | 125,482 | ||||||||||||
| Total costs and expenses | 58,628 | 53,117 | 223,306 | 226,042 | ||||||||||||
| Loss from operations | (45,880 | ) | (45,384 | ) | (181,134 | ) | (199,653 | ) | ||||||||
| Interest expense | (2,249 | ) | (1,912 | ) | (9,001 | ) | (10,734 | ) | ||||||||
| Loss on debt extinguishment | — | — | — | (12,630 | ) | |||||||||||
| Other income (expense), net | 1,782 | 1,203 | 7,011 | 7,623 | ||||||||||||
| Loss from continuing operations before income taxes | (46,347 | ) | (46,093 | ) | (183,124 | ) | (215,394 | ) | ||||||||
| Income tax provision | — | — | — | — | ||||||||||||
| Net loss from continuing operations | (46,347 | ) | (46,093 | ) | (183,124 | ) | (215,394 | ) | ||||||||
| Net income (loss) from discontinued operations, net of tax | 8,704 | (4,603 | ) | 351,148 | 243,901 | |||||||||||
| Net income (loss) | $ | (37,643 | ) | $ | (50,696 | ) | $ | 168,024 | $ | 28,507 | ||||||
| Net income (loss) per share: | ||||||||||||||||
| Net loss from continuing operations - basic and diluted | $ | (0.39 | ) | $ | (0.40 | ) | $ | (1.56 | ) | $ | (1.88 | ) | ||||
| Net income (loss) from discontinued operations - basic and diluted | $ | 0.07 | $ | (0.04 | ) | $ | 3.00 | $ | 2.13 | |||||||
| Net income (loss) per share - basic and diluted | $ | (0.31 | ) | $ | (0.44 | ) | $ | 1.43 | $ | 0.25 | ||||||
| Weighted-average number of shares used in computing net income (loss) per share: | ||||||||||||||||
| Basic and diluted | 120,369,638 | 115,418,069 | 117,143,457 | 114,553,537 | ||||||||||||
| Coherus Oncology, Inc. Condensed Consolidated Balance Sheets (in thousands) | |||||||
| December 31, | December 31, | ||||||
| 2025 (unaudited) | 2024* | ||||||
| Assets | |||||||
| Cash and cash equivalents | $ | 88,879 | $ | 125,987 | |||
| Investments in marketable securities | 83,246 | — | |||||
| Trade receivables, net | 17,815 | 111,324 | |||||
| TSA receivables, net | 603 | 11,010 | |||||
| Inventory | 3,172 | 4,207 | |||||
| Intangible assets, net | 46,239 | 53,646 | |||||
| Other assets | 18,389 | 25,936 | |||||
| Assets of discontinued operations | — | 116,423 | |||||
| Total assets | $ | 258,343 | $ | 448,533 | |||
| Liabilities and Stockholders’ Equity (Deficit) | |||||||
| Accrued rebates, fees and reserve | $ | 30,397 | $ | 164,867 | |||
| TSA payables and accrued liabilities | 65,065 | 11,026 | |||||
| Term loan | 37,051 | 36,698 | |||||
| Convertible notes | 121 | 228,229 | |||||
| Other liabilities | 64,695 | 139,703 | |||||
| Total stockholders' equity (deficit) | 61,014 | (131,990 | ) | ||||
| Total liabilities and stockholders’ equity (deficit) | $ | 258,343 | $ | 448,533 | |||
* Amounts derived from our audited consolidated financial statements.
| Coherus Oncology, Inc. Condensed Consolidated Statements of Cash Flows (in thousands) | ||||||||||||||||
| Three Months Ended | Year Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2025 (unaudited) | 2024 (unaudited) | 2025 (unaudited) | 2024* | |||||||||||||
| Cash, cash equivalents and restricted cash at beginning of the period | $ | 103,592 | $ | 97,953 | $ | 126,250 | $ | 103,343 | ||||||||
| Net cash (used in) provided by operating activities | (19,716 | ) | 28,608 | (138,513 | ) | (20,440 | ) | |||||||||
| Purchases of investments in marketable securities | (14,262 | ) | — | (103,838 | ) | — | ||||||||||
| Proceeds from maturities of investments in marketable securities | 19,812 | — | 21,462 | 6,200 | ||||||||||||
| Proceeds from sale of investments in marketable securities | — | — | — | 8,688 | ||||||||||||
| Net cash (paid) received related to the Sale Transactions | (8,376 | ) | — | 470,305 | 227,823 | |||||||||||
| Milestone payments to Junshi Biosciences | — | — | (12,500 | ) | (12,500 | ) | ||||||||||
| Other investing activities, net | (12 | ) | (542 | ) | (342 | ) | 110 | |||||||||
| Net cash (used in) provided by investing activities | (2,838 | ) | (542 | ) | 375,087 | 230,321 | ||||||||||
| Proceeds from 2029 Term loan, net of debt discount and issuance costs | — | — | — | 36,979 | ||||||||||||
| Proceeds from (repayment of) Revenue Purchase and Sale Agreement, net of issuance costs | — | — | (47,652 | ) | 36,486 | |||||||||||
| Proceeds from issuance of common stock under Private Placement, net of issuance costs | 7,894 | — | 7,894 | — | ||||||||||||
| Proceeds from issuance of common stock under Sale Agreement, net of issuance costs | — | — | — | 1,455 | ||||||||||||
| Proceeds from purchase under the employee stock purchase plan | 165 | 241 | 353 | 926 | ||||||||||||
| Taxes paid related to net share settlement | — | (10 | ) | (283 | ) | (2,476 | ) | |||||||||
| Redemption of 2026 Convertible Notes, including transaction costs | — | — | (233,185 | ) | — | |||||||||||
| Repayment of 2027 Term Loans, premiums and make-whole | — | — | — | (260,387 | ) | |||||||||||
| Other financing activities, net | 22 | — | (832 | ) | 43 | |||||||||||
| Net cash provided by (used in) financing activities | 8,081 | 231 | (273,705 | ) | (186,974 | ) | ||||||||||
| Net (decrease) increase in cash, cash equivalents and restricted cash | (14,473 | ) | 28,297 | (37,131 | ) | 22,907 | ||||||||||
| Cash, cash equivalents and restricted cash at end of the period | $ | 89,119 | $ | 126,250 | $ | 89,119 | $ | 126,250 | ||||||||
* Amounts derived from our audited consolidated financial statements.
Non-GAAP Financial Measures
To supplement the financial results presented in accordance with GAAP, Coherus has also included in this press release non-GAAP net loss from continuing operations, and the related per share measures, which exclude from net loss from continuing operations and the related per share measures, stock-based compensation expense, amortization and impairments of intangible assets, loss on debt extinguishment, and change in fair value of our Royalty Fee Derivative Liability. These non-GAAP financial measures are not prepared in accordance with GAAP, do not serve as an alternative to GAAP and may be calculated differently than similar non-GAAP financial information disclosed by other companies. Coherus encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP financial information and the reconciliation between these presentations set forth below, to more fully understand Coherus’ business.
Coherus believes that the presentation of these non-GAAP financial measures provides useful supplemental information to, and facilitates additional analysis by, investors. In particular, Coherus believes that these non-GAAP financial measures, when considered together with its financial information prepared in accordance with GAAP, can enhance investors’ and analysts’ ability to meaningfully compare Coherus’ results from period to period, and to identify operating trends in Coherus’ business. Coherus also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate its business and to make operating decisions.
| CoherusOncology, Inc. Reconciliation of GAAP Net Loss from Continuing Operations to Non-GAAP Net Loss from Continuing Operations (in thousands, except share and per share data) (unaudited) | ||||||||||||||||
| Three Months Ended | Year Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| GAAP net loss from continuing operations | $ | (46,347 | ) | $ | (46,093 | ) | $ | (183,124 | ) | $ | (215,394 | ) | ||||
| Adjustments: | ||||||||||||||||
| Stock-based compensation expense | 2,784 | 6,007 | 16,319 | 26,120 | ||||||||||||
| Loss on debt extinguishment | — | — | — | 12,630 | ||||||||||||
| Write-down of intangible assets and remeasurement of contingent consideration liabilities, net | 2,518 | — | 4,164 | 6,772 | ||||||||||||
| Change in fair value of Royalty Fee Derivative Liability | — | — | 810 | — | ||||||||||||
| Amortization of intangible assets | 625 | 667 | 2,611 | 3,351 | ||||||||||||
| Non-GAAP net loss from continuing operations | $ | (40,420 | ) | $ | (39,419 | ) | $ | (159,220 | ) | $ | (166,521 | ) | ||||
| GAAP | ||||||||||||||||
| Net loss per share from continuing operations, basic and diluted | $ | (0.39 | ) | $ | (0.40 | ) | $ | (1.56 | ) | $ | (1.88 | ) | ||||
| Shares used in computing basic and diluted net loss per share | 120,369,638 | 115,418,069 | 117,143,457 | 114,553,537 | ||||||||||||
| Non-GAAP | ||||||||||||||||
| Net loss per share from continuing operations, basic and diluted | $ | (0.34 | ) | $ | (0.34 | ) | $ | (1.36 | ) | $ | (1.45 | ) | ||||
| Shares used in computing basic and diluted net loss per share | 120,369,638 | 115,418,069 | 117,143,457 | 114,553,537 | ||||||||||||
FAQ
How much did Coherus (CHRS) report for LOQTORZI net revenue in 2025?
What debt reduction did Coherus (CHRS) achieve by year-end 2025?
How much cash did Coherus (CHRS) hold at December 31, 2025 and what does it include?
When will Coherus (CHRS) report clinical readouts for tagmokitug and casdozokitug in 2026?
What were the key clinical efficacy signals Coherus (CHRS) highlighted for casdozokitug?
What is the shareholder impact of Coherus’s recent equity financings (CHRS)?
